6 hours Sage Therapeutics Stock Down Almost 40% in 3 Months: Here’s Why Zacks
The pipeline setbacks related to SAGE’s neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on the stock.
The pipeline setbacks related to SAGE’s neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on the stock.